Guilin Sanjin Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Guilin Sanjin Pharmaceutical Co., Ltd. carries a market capitalization of 7.93B, placing it among publicly traded companies globally. Its enterprise value stands at 7.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.93B |
| Enterprise Value | 7.32B |
Share Statistics
Guilin Sanjin Pharmaceutical Co., Ltd. currently has 587.57M shares outstanding.
| Shares Outstanding | 587.57M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guilin Sanjin Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 16.42. The price-to-sales ratio is 3.92, and the price-to-book ratio stands at 3.92.
| PE Ratio | 16.42 |
| PS Ratio | 3.92 |
| PB Ratio | 3.92 |
| P/TBV Ratio | 2.79 |
| P/FCF Ratio | 70.64 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guilin Sanjin Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 13.26 and an EV/FCF ratio of 58.89. The EV/Sales ratio of 3.44 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.26 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.44 |
| EV / EBITDA | 13.26 |
| EV / EBIT | 13.26 |
| EV / FCF | 58.89 |
Financial Position
Guilin Sanjin Pharmaceutical Co., Ltd. maintains a current ratio of 2.79, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.55, indicating elevated leverage, while an interest coverage ratio of 70.63 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.79 |
| Quick Ratio | 1.93 |
| Debt / Equity | 20.55 |
| Debt / EBITDA | 1.17 |
| Interest Coverage | 70.63 |
Financial Efficiency
Guilin Sanjin Pharmaceutical Co., Ltd. posts a return on equity of 24.79 and a return on invested capital of 12.20.
| Return on Equity (ROE) | 24.79 |
| Return on Assets (ROA) | 12.62 |
| Return on Invested Capital (ROIC) | 12.20 |
| Return on Capital Employed (ROCE) | 19.67 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.34 |
Taxes
Over the trailing twelve months, Guilin Sanjin Pharmaceutical Co., Ltd. has paid 123.27M in income taxes, reflecting an effective tax rate of 19.55.
| Income Tax | 123.27M |
| Effective Tax Rate | 19.55 |
Stock Price Statistics
Guilin Sanjin Pharmaceutical Co., Ltd.'s stock has declined approximately -7.66074% over the past 52 weeks. The 50-day moving average sits at 13.40, while the 200-day moving average is 14.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.66074% |
| 50-Day Moving Average | 13.40 |
| 200-Day Moving Average | 14.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guilin Sanjin Pharmaceutical Co., Ltd. generated 2.12B in revenue and converted that into 507.39M in net income, yielding earnings per share of 0.87. EBITDA reached 551.90M, while operating income came in at 551.90M.
| Revenue | 2.12B |
| Gross Profit | 1.57B |
| Operating Income | 551.90M |
| Pretax Income | 630.65M |
| Net Income | 507.39M |
| EBITDA | 551.90M |
| EBIT | 551.90M |
| Earnings Per Share (EPS) | 0.87 |
Balance Sheet
Guilin Sanjin Pharmaceutical Co., Ltd. holds 1.66B in cash and equivalents against 643.27M in total debt, resulting in a net debt position of -532.00M. Total book value stands at 2.12B, with working capital of 1.54B providing operational flexibility.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 643.27M |
| Net Debt | -532.00M |
| Equity (Book Value) | 2.12B |
| Book Value Per Share | 3.65 |
| Working Capital | 1.54B |
Cash Flow
After subtracting -117.96M in capital expenditures, free cash flow totaled -117.96M - equivalent to -0.20 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -117.96M |
| Free Cash Flow | -117.96M |
| FCF Per Share | -0.20 |
Margins
Guilin Sanjin Pharmaceutical Co., Ltd. operates with a gross margin of 73.84, reflecting its pricing power and cost economics. The operating margin of 25.99 and net profit margin of 23.89 provide insight into operational efficiency.
| Gross Margin | 73.84 |
| Operating Margin | 25.99 |
| Pretax Margin | 29.69 |
| Profit Margin | 23.89 |
| EBITDA Margin | 25.99 |
Dividends & Yields
The company's payout ratio of 70.61 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.62 |
| Dividend Yield | N/A |
| Payout Ratio | 70.61 |
| Shareholder Yield | 1.80 |
| FCF Yield | 1.42 |
Stock Splits
Guilin Sanjin Pharmaceutical Co., Ltd.'s most recent stock split took place on April 21, 2011 with a 10:13 split ratio.
| Last Split Date | 4/21/2011 |
| Split Ratio | 10:13 |
Scores
Guilin Sanjin Pharmaceutical Co., Ltd. posts an Altman Z-Score of 6.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.49 |